Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Myeloproliferative syndromes]

A Ganser1

  • 1Medizinische Hochschule, Abteilung für Hämatologie und Onkologie, Hannover.

Therapeutische Umschau. Revue Therapeutique
|February 1, 1996
PubMed
Summary
This summary is machine-generated.

Myelodysplastic syndromes (MDS) are stem cell disorders causing low blood counts and potentially acute myeloid leukemia. Treatment focuses on supportive care, with options like erythropoietin, chemotherapy, or bone marrow transplant depending on patient factors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT.

Bone marrow transplantation·2023
Same author

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Scientific reports·2023
Same author

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Bone marrow transplantation·2020
Same author

Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.

Bone marrow transplantation·2019
Same author

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Leukemia·2019
Same author

Acquired long QT syndrome during conditioning for allogeneic stem cell transplantation-are we aware of this side effect?

Annals of hematology·2018
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Context:

  • Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
  • Characterized by ineffective hematopoiesis, leading to cytopenias (anemia, thrombocytopenia, neutropenia).
  • Approximately one-third of MDS patients progress to acute myeloid leukemia (AML).

Purpose:

  • To outline the clinical presentation and current therapeutic strategies for myelodysplastic syndromes.
  • To differentiate treatment approaches based on disease severity, patient age, and donor availability.

Summary:

  • MDS involves deregulated bone marrow cell proliferation and differentiation.
  • Supportive care is primary, with G-CSF for neutropenia/infection and erythropoietin for anemia.
  • Aggressive chemotherapy for advanced MDS; allogeneic bone marrow transplant is curative for younger patients with a matched sibling.

Related Experiment Videos

Impact:

  • Highlights the importance of individualized treatment for MDS patients.
  • Emphasizes the role of supportive care and targeted therapies.
  • Defines criteria for considering bone marrow transplantation as a curative option.